ReviewNature protocols2026
Secreted luciferases as a minimally invasive 3R-compliant tool for accurate monitoring of tumor burden.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Preclinical mouse models are indispensable in cancer research, providing insights into tumor biology and therapeutic responses. This protocol describes a minimally invasive blood-based tumor monitoring approach using secreted luciferases for longitudinal tracking of tumor burden in transplantable xenografts and genetically engineered mouse models. Unlike intracellular luciferases used in bioluminescence imaging, secreted luciferases are actively released into circulation, enabling precise quantification from microliter-scale blood samples. We describe a transplantable model, where tumor cells are labeled in vitro using lentiviral transduction before engraftment. Orthogonal secreted luciferases enable multiplexed analysis of distinct tumor populations within a single host, reducing animal numbers and enhancing data density. We also describe an autochthonous lung cancer model, where intratracheal adenoviral delivery of Cre recombinase and CRISPR nucleases induces tumorigenesis through somatic genome editing while activating a conditional secreted luciferase reporter transgene. Tumor-bearing mice undergo routine blood sampling, with luciferase activity measured ex vivo to quantify viable tumor burden. Compared to imaging techniques, this method eliminates anesthesia and contrast agents, minimizing animal stress and enabling frequent monitoring with superior temporal resolution and reduced logistical complexity. The protocol requires only standard molecular biology skills and basic mouse handling expertise. While tumor labeling and growth duration is model dependent, blood sampling requires ~5 min per animal, with all samples from one cohort processed and measured together within 2 h. This approach provides an accessible, cost-effective and scalable alternative to imaging-based tumor monitoring, that is aligned with the 3Rs principles, offering a powerful and ethically sound platform for preclinical cancer research.
Indexed as
Identifiers
41634147What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.